{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:01:58Z","timestamp":1787580118181,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA154982-04"],"award-info":[{"award-number":["R01CA154982-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4402-x","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T12:44:59Z","timestamp":1525265099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-9252","authenticated-orcid":false,"given":"Elizabeth G.","family":"Liles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne C.","family":"Feldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Mosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore R.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"4402_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2018. \n                    https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2018.html\n                    \n                  . Accessed\u00a029 Apr 2018."},{"key":"4402_CR2","volume":"1","author":"P Hewitson","year":"2007","unstructured":"Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;(1):CD001216.","journal-title":"Hemoccult. Cochrane Database Syst Rev."},{"issue":"27","key":"4402_CR3","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1056\/NEJM199312303292701","volume":"329","author":"SJ Winawer","year":"1993","unstructured":"Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977\u201381.","journal-title":"N Engl J Med"},{"issue":"9726","key":"4402_CR4","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S0140-6736(10)60551-X","volume":"375","author":"WS Atkin","year":"2010","unstructured":"Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624\u201333.","journal-title":"Lancet"},{"issue":"6","key":"4402_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jama.2014.8266","volume":"312","author":"O Holme","year":"2014","unstructured":"Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, Eide TJ, Skovlund E, Schneede J, Tveit KM, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606\u201315.","journal-title":"JAMA"},{"issue":"17","key":"4402_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/djr284","volume":"103","author":"N Segnan","year":"2011","unstructured":"Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, Andreoni B, Arrigoni A, Bisanti L, Casella C, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4402_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.gastro.2008.03.040","volume":"135","author":"LG van Rossum","year":"2008","unstructured":"van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135(1):82\u201390.","journal-title":"Gastroenterology"},{"issue":"5-6","key":"4402_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ypmed.2010.03.010","volume":"50","author":"RM Hoffman","year":"2010","unstructured":"Hoffman RM, Steel SR, Yee EF, Massie L, Schrader RM, Murata GH. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med. 2010;50(5-6):297\u20139.","journal-title":"Prev Med"},{"issue":"2","key":"4402_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1258\/0969141053908357","volume":"12","author":"A Federici","year":"2005","unstructured":"Federici A, Giorgi RP, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen. 2005;12(2):83\u20138.","journal-title":"J Med Screen"},{"issue":"7","key":"4402_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.bjc.6604961","volume":"100","author":"L Hol","year":"2009","unstructured":"Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100(7):1103\u201310.","journal-title":"Br J Cancer"},{"issue":"3","key":"4402_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1155\/2012\/486328","volume":"26","author":"L Rabeneck","year":"2012","unstructured":"Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, Messersmith H, Lewis N. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012;26(3):131\u201347.","journal-title":"Can J Gastroenterol"},{"issue":"5","key":"4402_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1053\/j.gastro.2016.08.053","volume":"152","author":"DJ Robertson","year":"2017","unstructured":"Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology. 2017;152(5):1217\u201337. e1213","journal-title":"Gastroenterology"},{"issue":"23","key":"4402_CR13","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1001\/jama.2016.5989","volume":"315","author":"US Preventive Services Task Force: Screening for colorectal cancer","year":"2016","unstructured":"US Preventive Services Task Force: Screening for colorectal cancer. US preventive services task force recommendation statement. JAMA. 2016;315(23):2564\u201375.","journal-title":"JAMA"},{"issue":"10","key":"4402_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.7326\/M14-2326","volume":"162","author":"TJ Wilt","year":"2015","unstructured":"Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162(10):718\u201325.","journal-title":"Ann Intern Med"},{"issue":"3","key":"4402_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.7326\/M13-1484","volume":"160","author":"JK Lee","year":"2014","unstructured":"Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171.","journal-title":"Ann Intern Med"},{"issue":"9","key":"4402_CR16","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1038\/ajg.2010.181","volume":"105","author":"JE Allison","year":"2010","unstructured":"Allison JE. FIT: a valuable but underutilized screening test for colorectal cancer-it's time for a change. Am J Gastroenterol. 2010;105(9):2026\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"4402_CR17","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.3748\/wjg.v23.i20.3632","volume":"23","author":"M Navarro","year":"2017","unstructured":"Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017;23(20):3632\u201342.","journal-title":"World J Gastroenterol"},{"key":"4402_CR18","unstructured":"US National Institutes of Health. Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01239082\n                    \n                  . Accessed Sept 6 2016."},{"issue":"8","key":"4402_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa1108895","volume":"366","author":"E Quintero","year":"2012","unstructured":"Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, Andreu M, Carballo F, Morillas JD, Hernandez C, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366(8):697\u2013706.","journal-title":"N Engl J Med"},{"issue":"7","key":"4402_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/M15-0983","volume":"164","author":"CD Jensen","year":"2016","unstructured":"Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456\u201363.","journal-title":"Ann Intern Med"},{"issue":"11","key":"4402_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/jnci\/djs190","volume":"104","author":"CG Fraser","year":"2012","unstructured":"Fraser CG, Allison JE, Halloran SP, Young GP. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012;104(11):810\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4402_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/CEJ.0000000000000084","volume":"23","author":"DM Mosen","year":"2014","unstructured":"Mosen DM, Liles EG, Feldstein AC, Perrin N, Rosales AG, Keast E, Smith DH. Participant uptake of the fecal immunochemical test decreases with the two-sample regimen compared with one-sample FIT. Eur J Cancer Prev. 2014;23(6):516\u201323.","journal-title":"Eur J Cancer Prev"},{"key":"4402_CR23","unstructured":"National Institute for Health and Clinical Excellence. Suspected cancer, recognition and referral. 1.3 Lower gastrointestinal tract cancers [Internet]. [Updated 2015 June 23]. \n                    https:\/\/www.nice.org.uk\/guidance\/NG12\/chapter\/1-Recommendations-organised-by-site-of-cancer#lower-gastrointestinal-tract-cancers\n                    \n                  . Accessed Sept 6 2016."},{"key":"4402_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-230X-11-65","volume":"11","author":"BA Adelstein","year":"2011","unstructured":"Adelstein BA, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. BMC Gastroenterol. 2011;11:65.","journal-title":"BMC Gastroenterol"},{"key":"4402_CR25","doi-asserted-by":"publisher","first-page":"c1269","DOI":"10.1136\/bmj.c1269","volume":"340","author":"P Jellema","year":"2010","unstructured":"Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, de Vet HC. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ. 2010;340:c1269.","journal-title":"BMJ"},{"issue":"11","key":"4402_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/gut.2008.159723","volume":"57","author":"AC Ford","year":"2008","unstructured":"Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut. 2008;57(11):1545\u201353.","journal-title":"Gut"},{"issue":"7","key":"4402_CR27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1053\/j.gastro.2013.03.002","volume":"144","author":"EM van Heijningen","year":"2013","unstructured":"van Heijningen EM, Lansdorp-Vogelaar I, Kuipers EJ, Dekker E, Lesterhuis W, Ter Borg F, Vecht J, De Jonge V, Spoelstra P, Engels L, et al. Features of adenoma and colonoscopy associated with recurrent colorectal neoplasia based on a large community-based study. Gastroenterology. 2013;144(7):1410\u20138.","journal-title":"Gastroenterology"},{"issue":"3","key":"4402_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/j.gastro.2012.06.001","volume":"143","author":"DA Lieberman","year":"2012","unstructured":"Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology. 2012;143(3):844\u201357.","journal-title":"Gastroenterology"},{"issue":"3","key":"4402_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"key":"4402_CR30","volume-title":"Analyzing receiver operating characteristic curves with SAS","author":"M G\u00f6nen","year":"2007","unstructured":"G\u00f6nen M. Analyzing receiver operating characteristic curves with SAS. Cary, NC: SAS Institute Inc.; 2007."},{"issue":"9","key":"4402_CR31","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/ajg.2010.179","volume":"105","author":"DI Park","year":"2010","unstructured":"Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105(9):2017\u201325.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"4402_CR32","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2036.2009.03946.x","volume":"29","author":"P Rozen","year":"2009","unstructured":"Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther. 2009;29(8):906\u201317.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"4402_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cgh.2009.05.032","volume":"7","author":"SJ Heitman","year":"2009","unstructured":"Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1272\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"4402_CR34","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.dld.2012.03.015","volume":"44","author":"J Faivre","year":"2012","unstructured":"Faivre J, Dancourt V, Manfredi S, Denis B, Durand G, Gendre I, Bidan JM, Jard C, Levillain R, Jung S, et al. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme. Dig Liver Dis. 2012;44(8):700\u20134.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"4402_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/gutjnl-2014-308957","volume":"66","author":"A Kapidzic","year":"2017","unstructured":"Kapidzic A, van Roon AH, van Leerdam ME, van Vuuren AJ, van Ballegooijen M, Lansdorp-Vogelaar I, Spijker W, Izelaar K, Hol L, Kuipers EJ. Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut. 2017;66(1):118\u201323.","journal-title":"Gut"},{"issue":"5","key":"4402_CR36","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1053\/j.gastro.2013.01.042","volume":"144","author":"T Raginel","year":"2013","unstructured":"Raginel T, Puvinel J, Ferrand O, Bouvier V, Levillain R, Ruiz A, Lantieri O, Launoy G, Guittet L. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology. 2013;144(5):918\u201325.","journal-title":"Gastroenterology"},{"issue":"10","key":"4402_CR37","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/ajg.2012.249","volume":"107","author":"TR de Wijkerslooth","year":"2012","unstructured":"de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, Stegeman I, Kraaijenhagen RA, Fockens P, van Leerdam ME, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107(10):1570\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4402_CR38","first-page":"405","volume":"18","author":"S Aniwan","year":"2017","unstructured":"Aniwan S, Ratanachu Ek T, Pongprasobchai S, Limsrivilai J, Praisontarangkul OA, Pisespongsa P, Mairiang P, Sangchan A, Sottisuporn J, Wisedopas N, et al. The optimal cut-off level of the fecal immunochemical test for colorectal cancer screening in a country with limited colonoscopy resources: a multi-center study from Thailand. Asian Pac J Cancer Prev. 2017;18(2):405\u201312.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"4402_CR39","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1007\/s10620-013-2819-2","volume":"58","author":"JM Cha","year":"2013","unstructured":"Cha JM, Lee JI, Joo KR, Shin HP, Jeun JW, Lim JU. Use of a low cut-off value for the fecal immunochemical test enables better detection of proximal neoplasia. Dig Dis Sci. 2013;58(11):3256\u201362.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"4402_CR40","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1377\/hlthaff.2008.0898","volume":"29","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bobashev G, Morris RJ. When budgets are tight, there are better options than colonoscopies for colorectal cancer screening. Health Aff (Millwood). 2010;29(9):1734\u201340.","journal-title":"Health Aff (Millwood)"},{"issue":"16","key":"4402_CR41","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1002\/cncr.30070","volume":"122","author":"DA Joseph","year":"2016","unstructured":"Joseph DA, Meester RG, Zauber AG, Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M. Colorectal cancer screening: estimated future colonoscopy need and current volume and capacity. Cancer. 2016;122(16):2479\u201386.","journal-title":"Cancer"},{"issue":"4","key":"4402_CR42","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s10900-016-0165-y","volume":"41","author":"A Oluloro","year":"2016","unstructured":"Oluloro A, Petrik AF, Turner A, Kapka T, Rivelli J, Carney PA, Saha S, Coronado GD. Timeliness of colonoscopy after abnormal fecal test results in a safety net practice. J Community Health. 2016;41(4):864\u201370.","journal-title":"J Community Health"},{"key":"4402_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13012-015-0227-z","volume":"10","author":"EG Liles","year":"2015","unstructured":"Liles EG, Schneider JL, Feldstein AC, Mosen DM, Perrin N, Rosales AG, Smith DH. Implementation challenges and successes of a population-based colorectal cancer screening program: a qualitative study of stakeholder perspectives. Implement Sci. 2015;10:41.","journal-title":"Implement Sci"},{"issue":"4","key":"4402_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1503\/cmaj.050090","volume":"174","author":"AW Rutjes","year":"2006","unstructured":"Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ. 2006;174(4):469\u201376.","journal-title":"CMAJ"},{"issue":"9","key":"4402_CR45","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/(SICI)1097-0258(19970515)16:9<981::AID-SIM510>3.0.CO;2-N","volume":"16","author":"H Brenner","year":"1997","unstructured":"Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med. 1997;16(9):981\u201391.","journal-title":"Stat Med"},{"issue":"7","key":"4402_CR46","doi-asserted-by":"publisher","first-page":"598","DOI":"10.7326\/0003-4819-137-7-200210010-00011","volume":"137","author":"SA Mulherin","year":"2002","unstructured":"Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med. 2002;137(7):598\u2013602.","journal-title":"Ann Intern Med"},{"issue":"6","key":"4402_CR47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1055-9965.EPI-12-0192","volume":"21","author":"JA Shapiro","year":"2012","unstructured":"Shapiro JA, Klabunde CN, Thompson TD, Nadel MR, Seeff LC, White A. Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev. 2012;21(6):895\u2013904.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"4402_CR48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11605-015-3042-6","volume":"20","author":"QM Hatch","year":"2016","unstructured":"Hatch QM, Kniery KR, Johnson EK, Flores SA, Moeil DL, Thompson JJ, Maykel JA, Steele SR. Screening or symptoms? How do we detect colorectal cancer in an equal access health care system? J Gastrointest Surg. 2016;20(2):431\u20138.","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"4402_CR49","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.89.9.1322","volume":"89","author":"RE Glasgow","year":"1999","unstructured":"Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322\u20137.","journal-title":"Am J Public Health"},{"issue":"3","key":"4402_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s13142-016-0461-1","volume":"7","author":"GD Coronado","year":"2017","unstructured":"Coronado GD, Schneider JL, Petrik A, Rivelli J, Taplin S, Green BB. Implementation successes and challenges in participating in a pragmatic study to improve colon cancer screening: perspectives of health center leaders. Transl Behav Med. 2017;7(3):557\u201366.","journal-title":"Transl Behav Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4402-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:24:39Z","timestamp":1589462679000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4402"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4402-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"20 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Kaiser Permanente Northwest Institutional Review Board approved the study on August 23, 2011. Participants who gave verbal consent to be part of the study received an information sheet in the mail (with the 2 FIT kits enclosed) explaining the benefits, risks and costs of the study and outlining other elements of informed consent. Given that there were no study visits, the Institutional Review Board approved verbal consent with distribution of the information sheet, to enable feasibility of study completion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"509"}}